×
About 1,321 results

ALLMedicine™ Primary CNS Lymphoma Center

Research & Reviews  649 results

The value of bone marrow biopsy for staging of patients with primary CNS lymphoma.
https://doi.org/10.1093/neuonc/noab109
Neuro-oncology Margold M, Seidel S et. al.

May 13th, 2021 - In patients with presumed primary CNS lymphoma (PCNSL) a systemic manifestation is found only in a small minority. Although bone marrow biopsy (BMB) is recommended for staging, its diagnostic value is unclear. A retrospective analysis of 392 patie...

Successful treatment of EBV-associated Primary CNS Lymphoma due to PTLD, with Ibrutinib...
https://doi.org/10.1111/ajt.16628
American Journal of Transplantation : Official Journal Of... Law SC, Hoang T et. al.

May 4th, 2021 - Primary central nervous system lymphoma (PCNSL) occurring following organ transplantation (post-transplantation lymphoproliferative disorder 'PTLD') is a highly aggressive non-Hodgkin lymphoma. It is typically treated with high-dose methotrexate-b...

Sorting biologic subtypes of primary CNS lymphoma.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7976509
Blood Roschewski M, Phelan JD

Mar 18th, 2021 - Sorting biologic subtypes of primary CNS lymphoma.|2021|Roschewski M,Phelan JD,|

Consensus Recommendations for MRI and PET Imaging of Primary Central Nervous System Lym...
https://doi.org/10.1093/neuonc/noab020
Neuro-oncology Barajas RF, Politi LS et. al.

Feb 9th, 2021 - Advanced molecular and pathophysiologic characterization of Primary Central Nervous System Lymphoma (PCNSL) has revealed insights into promising targeted therapeutic approaches. Medical imaging plays a fundamental role in PCNSL diagnosis, staging,...

Neurocognitive functioning and radiologic changes in primary CNS lymphoma patients: res...
https://doi.org/10.1093/neuonc/noab021
Neuro-oncology van der Meulen M, Dirven L et. al.

Feb 9th, 2021 - To analyze the effect of treatment on neurocognitive functioning and the association of neurocognition with radiological abnormalities in primary central nervous system lymphoma (PCNSL). 199 patients from a phase III trial (HOVON 105/ALLG NHL 24),...

see more →

Clinicaltrials.gov  661 results

The value of bone marrow biopsy for staging of patients with primary CNS lymphoma.
https://doi.org/10.1093/neuonc/noab109
Neuro-oncology Margold M, Seidel S et. al.

May 13th, 2021 - In patients with presumed primary CNS lymphoma (PCNSL) a systemic manifestation is found only in a small minority. Although bone marrow biopsy (BMB) is recommended for staging, its diagnostic value is unclear. A retrospective analysis of 392 patie...

Successful treatment of EBV-associated Primary CNS Lymphoma due to PTLD, with Ibrutinib...
https://doi.org/10.1111/ajt.16628
American Journal of Transplantation : Official Journal Of... Law SC, Hoang T et. al.

May 4th, 2021 - Primary central nervous system lymphoma (PCNSL) occurring following organ transplantation (post-transplantation lymphoproliferative disorder 'PTLD') is a highly aggressive non-Hodgkin lymphoma. It is typically treated with high-dose methotrexate-b...

Sorting biologic subtypes of primary CNS lymphoma.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7976509
Blood Roschewski M, Phelan JD

Mar 18th, 2021 - Sorting biologic subtypes of primary CNS lymphoma.|2021|Roschewski M,Phelan JD,|

Consensus Recommendations for MRI and PET Imaging of Primary Central Nervous System Lym...
https://doi.org/10.1093/neuonc/noab020
Neuro-oncology Barajas RF, Politi LS et. al.

Feb 9th, 2021 - Advanced molecular and pathophysiologic characterization of Primary Central Nervous System Lymphoma (PCNSL) has revealed insights into promising targeted therapeutic approaches. Medical imaging plays a fundamental role in PCNSL diagnosis, staging,...

Neurocognitive functioning and radiologic changes in primary CNS lymphoma patients: res...
https://doi.org/10.1093/neuonc/noab021
Neuro-oncology van der Meulen M, Dirven L et. al.

Feb 9th, 2021 - To analyze the effect of treatment on neurocognitive functioning and the association of neurocognition with radiological abnormalities in primary central nervous system lymphoma (PCNSL). 199 patients from a phase III trial (HOVON 105/ALLG NHL 24),...

see more →

News  11 results

Primary CNS lymphoma: R-CHOP hits back
https://www.mdedge.com/hematology-oncology/article/210341/b-cell-lymphoma/primary-cns-lymphoma-r-chop-hits-back?channel=59374
Vanja Zeremski, MD, Thomas Fischer, MD

Oct 17th, 2019 - Primary central nervous system lymphoma (PCNSL) is a rare and aggressive form of non-Hodgkin lymphoma solely confined to the CNS. The majority of PCNSL histologically presents as diffuse large B-cell lymphoma (DLBCL).

Rituximab boosts survival in primary CNS lymphoma
https://www.mdedge.com/hematology-oncology/article/197142/b-cell-lymphoma/rituximab-boosts-survival-primary-cns-lymphoma?channel=59374
Will Pass

Mar 22nd, 2019 - For patients with primary central nervous system lymphoma (PCNSL), adding rituximab to combination high-dose methotrexate and temozolomide significantly boosted the 5-year overall survival rate, according to a retrospective study. The triplet comb.

AUDIO: Immunotherapy’s role in NHL
https://www.mdedge.com/hematologynews/nhlhub/article/156128/aggressive-lymphomas/audio-immunotherapys-role-nhl
Mary Ellen Schneider

Jan 11th, 2018 - ATLANTA – The use of immune checkpoint blockade is increasingly becoming standard therapy in Hodgkin lymphoma, but this approach has so far garnered mixed results in non-Hodgkin lymphoma, Stephen Ansell, MD, PhD, said at the annual meeting of the.

Serious AEs reported too late in lymphoma trial
https://www.mdedge.com/hematology-oncology/article/188810/lymphoma-plasma-cell-disorders/serious-aes-reported-too-late-lymphoma-trial
HT Staff

Oct 24th, 2016 - NIH Director Francis Collins Photo by Bill Branson Investigators conducting a phase 1 trial failed to follow requirements for reporting serious adverse events (AEs), including deaths, according to officials from the National Cancer Institute (NCI).

Temsirolimus results in good but short-duration responses in primary CNS lymphoma
https://www.mdedge.com/neurology/article/107329/aggressive-lymphomas/temsirolimus-results-good-short-duration-responses
Neil Osterweil

Mar 14th, 2016 - Single-agent therapy with temsirolimus was active in patients with relapsed/refractory primary central nervous system lymphoma, but most of the responses were short lived, results of a phase II trial show. Among 37 patients with primary CNS lympho.

see more →